| Primary |
| Chronic Lymphocytic Leukaemia |
100.0% |
|
| Neoplasm Malignant |
50.0% |
| White Blood Cell Count Decreased |
50.0% |
|
| Secondary |
| Non-hodgkin's Lymphoma |
18.6% |
| Chronic Lymphocytic Leukaemia |
15.9% |
| Diffuse Large B-cell Lymphoma |
11.0% |
| Mantle Cell Lymphoma |
8.1% |
| Lymphoma |
7.0% |
| Product Used For Unknown Indication |
6.0% |
| Idiopathic Thrombocytopenic Purpura |
3.7% |
| B-cell Lymphoma |
3.0% |
| Chemotherapy |
3.0% |
| Evans Syndrome |
2.8% |
| Central Nervous System Lymphoma |
2.4% |
| Metastases To Meninges |
2.3% |
| Rheumatoid Arthritis |
2.3% |
| Ill-defined Disorder |
2.2% |
| Systemic Lupus Erythematosus |
2.1% |
| Drug Use For Unknown Indication |
2.0% |
| Gastrooesophageal Reflux Prophylaxis |
2.0% |
| Burkitt's Lymphoma |
1.9% |
| Renal Transplant |
1.9% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Stage Iii |
1.7% |
|
| Hepatitis B |
8.7% |
| White Blood Cell Count Decreased |
7.8% |
| Blood Stem Cell Harvest Failure |
6.8% |
| Thrombocytopenia |
6.8% |
| Progressive Multifocal Leukoencephalopathy |
5.8% |
| Pyrexia |
5.8% |
| Therapy Non-responder |
5.8% |
| Weight Decreased |
5.8% |
| Pneumonia |
4.9% |
| Sepsis |
4.9% |
| Tricuspid Valve Incompetence |
4.9% |
| Anaemia |
3.9% |
| Epistaxis |
3.9% |
| Neutropenia |
3.9% |
| Off Label Use |
3.9% |
| Renal Failure |
3.9% |
| Septic Shock |
3.9% |
| Haemoglobin Decreased |
2.9% |
| Interstitial Lung Disease |
2.9% |
| Myelodysplastic Syndrome |
2.9% |
|
| Concomitant |
| Non-hodgkin's Lymphoma |
15.3% |
| Glycogen Storage Disease Type Ii |
12.0% |
| Liver Transplant |
10.9% |
| Immunosuppression |
8.2% |
| Renal Transplant |
7.1% |
| B-cell Lymphoma |
6.6% |
| Chronic Lymphocytic Leukaemia |
6.6% |
| Drug Use For Unknown Indication |
4.4% |
| Diffuse Large B-cell Lymphoma |
3.3% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Stage Iv |
3.3% |
| Product Used For Unknown Indication |
3.3% |
| Prophylaxis Against Graft Versus Host Disease |
3.3% |
| Systemic Lupus Erythematosus |
3.3% |
| Prophylaxis Against Transplant Rejection |
2.2% |
| Stem Cell Transplant |
2.2% |
| Antifungal Prophylaxis |
1.6% |
| Bone Marrow Transplant |
1.6% |
| Evans Syndrome |
1.6% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii |
1.6% |
| Mantle Cell Lymphoma |
1.6% |
|
| Thrombocytopenia |
11.4% |
| Vomiting |
11.4% |
| White Blood Cell Count Decreased |
11.4% |
| Sepsis |
7.6% |
| Transplant Rejection |
6.3% |
| Pneumocystis Jiroveci Pneumonia |
5.1% |
| Weight Decreased |
5.1% |
| No Therapeutic Response |
3.8% |
| Pancytopenia |
3.8% |
| Pneumonia |
3.8% |
| Reperfusion Arrhythmia |
3.8% |
| Urinary Tract Infection |
3.8% |
| Urine Output Decreased |
3.8% |
| Wheezing |
3.8% |
| Bk Virus Infection |
2.5% |
| Breast Cancer Female |
2.5% |
| Drug Ineffective For Unapproved Indication |
2.5% |
| Enterobacter Pneumonia |
2.5% |
| International Normalised Ratio Increased |
2.5% |
| Loss Of Consciousness |
2.5% |
|
